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ABBREVIATIONS 
 
AOR: Adjusted Odds Ratio 
AFB: Acid- Fast Bacilli 
AIDS: Acquired immune deficiency syndrome 
ART: Anti-retroviral therapy 
CI: Confidence interval 
CPT: Cotrimoxazole preventive therapy 
DHMT: District Health Management Team 
DOT: Directly observed therapy 
DOTS: Directly observed therapy short Course 
EPTB: Extra pulmonary tuberculosis 
ETR: Electronic TB Register 
HIV: Human immunodeficiency virus 
HR: Hazard ration 
IPT: Isoniazid preventive therapy 
IQR: Interquartile range 
 
MDG: Millennium Development Goal 
MDR-TB: Multi-drug resistant tuberculosis 
MOH: Ministry of Health 
MTB: Mycobacterium tuberculosis 
OR: Odds ratio 
PLWH: People Living With HIV 
PTB: Pulmonary tuberculosis 
SES: Socio-economic status 
WHO: World Health Organization 
XDR-TB: Extreme/extensively drug resistant tuberculosis 
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DEFINITIONS OF KEY TERMS 
 
Completed treatment: TB patient who has completed the intensive and continuation phases of TB 
treatment; may be cured or not. 
Cured: completion of the TB treatment with a smear negative result at 6/8 month 
 
Death: refers to the death while on the TB treatment with confirmed TB at the time of the death; 
regardless of cause. 
Demographic factors: refers to the age and gender. 
 
Extensive- Drug Resistance TB (XDR- TB): resistance to rifampicin, isoniazid and at least one of 
the other (second line) anti-TB drugs. 
Extra- pulmonary TB: refers to TB of organs other than the 
 
Multi- Drug Resistance TB (MDR- TB): resistance at least to the two most effective first line TB 
drugs (rifampicin and isoniazid). 
New Patient: a patient who never had treatment for TB or who has taken anti-TB treatment for less 
than one month, or patient previously treated and cured (two or more years ago) who is diagnosed 
with TB again. 
Pulmonary TB: refers to the disease involving the lung parenchyma. 
 
Retreatment patient (relapse): a patient previously treated for TB who has been declared cured or 
treatment completed, and is diagnosed with bacteriology positive TB. 
Treatment classification: is based on the site of TB, may be pulmonary TB or extra- pulmonary 
TB. 
Treatment group: refers to new patient or retreatment patient. 
 
Treatment outcomes: include-completed treatment, death, sputum smear conversion and treatment 
failure. 
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ABSTRACT 
Background: Botswana has one of the highest TB incidence rates in the world. Tuberculosis in 
those without HIV infection accounts for 13% of adult mortality and in those living with TB and 
HIV in Botswana account for 40% of annual adult mortality. Francistown is a health district with 
TB mortality rates in excess of 5% of diagnosed TB patients yearly.The aim of this study was to 
assess patient related factors and early warning signs (predictors) of death among TB patients on 
treatment in Francistown clinics in order to identify possible interventions. 
Methodology: A retrospective case-control study design was used in this study. The records of all 
patients treated for TB from January 2010 to November 2015 who met the study inclusion criteria 
were extracted from the district electronic register (ETR). Socio-demographic variables, clinical 
variables and treatment outcome were collected and analysed. Univariate and multivariate logistic 
regression techniques were used to assess the predictors of death and the Kaplan Meier plot to 
determine time to death while on treatment. 
Result: A total of 1718 participants were included in the study. The median age of the study 
population was 35 years (IQR: 29, 42). Of the study population, 56% were male. Most of the 
participants had pulmonary TB (78%). There was a very high HIV prevalence among the study 
population (74%). About 44% of participants had smear results at the start and at the completion 
of TB treatment. Of the 1718 participants 161 (95% CI 8.0-10.8) died during the course of TB 
treatment. Univariate analysis showed HIV status, extra-pulmonary TB and a history of TB 
treatment default to be associated with earlier death. Multivariate analysis of selected variables 
showed that being older (≥ 55 years old), HIV-positive, having a history of TB and extra- 
pulmonary TB are independent predictors of death while on TB treatment. The overall median 
time to death was 52 days. Lack of HIV-related intervention during TB treatment was a significant 
independent predictor of time to death (adjusted HR = 1.79; 95% CI 1.03 – 3.1; p = 0.037). 
Conclusion: Of the 1718 adult patients treated for TB in Francistown clinics from January 2010 
to November 2016, 161 (9%) died while on treatment. The predictors of death identified in the 
study include, prior history of TB infection, Extra-Pulmonary TB, HIV status, HIV-related 
intervention and over 55 years of age. Gender was not a predictor of death in this study. Their 
overall median time to death in the study was 52 days. Patients on treatment for the first time with 
no previous history of TB lived on average 150 days on TB treatment. All TB patients with HIV 
co-infection that did not receive Antiretroviral Therapy (ART) and or Cotrimoxazole Preventive 
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Therapy (CPT) died during the intensive phase of TB treatment. More than half of all deaths 
recorded in this study occurred during the intensive phase of TB treatment. After adjusting for 
gender, age, treatment classification, treatment group and HIV status and the lack of HIV-related 
interventionsduring TB treatment was the significant predictor of earlier death among patients with 
TB/HIV co-infection in this study. 
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CHAPTER 1 
 
 
 
BACKGROUND 
 
1.1 Introduction 
 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis. It 
typically affects the lungs (pulmonary TB) but can affect other sites in the body (extra-pulmonary 
TB (EPTB)). Tuberculosis is an airborne disease which is spread when people who are sick with 
pulmonary TB expel bacteria by coughing or sneezing. About 5 to 15% of the estimated two billion 
people infected with M. tuberculosis will develop TB disease during their lifetime (WHO, 2014). 
1.2 Global Tuberculosis Epidemiology 
 
In 1993, the World Health Organization (WHO) declared TB a global emergency of avoidable 
death in developing countries (WHO, 1993). A third of the world’s population are infected with 
tuberculosis (WHO, 2014). In 2014, there were 9.6 million TB infections (approximately six 
million were new) of which: 5.4 million men, 3.2 million women and one million children. About 
12% of all reported new TB infections in 2014 occurred in HIV-positive people (WHO, 2014). Of 
the global TB cases reported, 95% were recorded in developing countries and 98% of annual global 
TB-related deaths occurred in these countries (MOH, 2011). More than two thirds of TB cases 
occur in the economically productive 15 to 50 years age group, and the disease is responsible for 
25% of all avoidable deaths in developing countries (Woldeyohannes et al., 2011). Countries with 
a high prevalence of HIV, particularly those in sub-Saharan Africa, have witnessed a profound 
increase in the number of TB cases, with incidence rates increasing threefold over the last decade 
in some countries (MOH, 2011). The high prevalence of TB in some sub-Saharan African 
countries is attributed to the decreased levels of immunity among the HIV-positive population 
(Zachariah et al., 2002). Tuberculosis is ranked alongside HIV as a leading cause of death 
worldwide, having killed 1.5 million people in 2014 (WHO, 2014). Despite the huge financial and 
human investments in TB (disease diagnosis, care and treatment), it continues to be a global public 
health challenge. 
1.3 Epidemiology of Tuberculosis in Botswana 
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Tuberculosis is a public health emergency in Botswana; a country with one of the highest TB 
notification rates in the world. In 2011, the estimated TB incidence was close to four times the 
global equivalent at 455 per 100000 persons (MoH, 2013). Botswana experienced a decline in TB 
notification rates from 506 per 100000 in 1975 to 199 per 100 0000 in 1989 (MoH, 2007). 
However, the TB incidence rates more than doubled by the 1990s making the WHO rank Botswana 
among the countries with the highest TB incidence rates in the world (MoH, 2012). Tuberculosis 
is responsible for 13% of all adult mortality and 40% of mortality among people living with HIV 
(PLWH) in Botswana (MOH, 2007, Etard et al., 2006). Figure 1.1 below, illustrates the positive 
correlation between HIV prevalence and the TB notification rate in the Botswanan population. 
 
 
Figure 1.1: Trends in TB case notification rates and HIV prevalence in Botswana (Source: BNTP 
Annual Reports 2013). 
The Botswana AIDS Impact Survey estimated HIV prevalence at 18.5% among the population 
aged 18 months and above (Botswana AIDS Impact Survey IV, 2013). The population aged 
between 35 and39 and 45 and 49 years had the highest prevalence estimated at 44% and 42% 
respectively (Botswana AIDS Impact Survey IV, 2013). Among the poorer parts of the population, 
around 64% of HIV-positive patients were found to be infected with TB (MoH, 2013). Based on 
the WHO clinical staging, the Botswana National Antiretroviral Treatment (ART) programme has 
listed TB infection as a major opportunistic infection requiring the commencement of ART 
irrespective of CD4 count. Due to the co-morbidities of TB and HIV, the national ART and TB 
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programmemes have been working closely in an effort to address these dual epidemics. The overall 
treatment success rate for 7254 notified patients in 2013 was 73% (WHO, 2014). The treatment 
success rate among HIV-positive patients co-infected with TB was lower at 71% (WHO, 2014). 
The mortality rate amongst the HIV-positive patients co-infected with TB was almost 12%, 
compared to the 7% amongst the HIV-negative patients (The Global Fund, 2015). 
1.4 Tuberculosis in Francistown 
 
Francistown is among the health districts with a high case notification rate (Figure 1.2) and a high 
TB mortality rate in excess of 5% (The Global Fund, 2015). The unpublished Francistown District 
Health Management Team report documented TB mortality from 2010 to 2014 at 5%, 11%, 9%, 
7%, 12% respectively. 
 
 
 
Figure 1.2: Case notifications rates per 100000 population in the districts (2012 and 2013) 
(Source: The Global Fund, 2015: Botswana TB and HIV Concept Note). 
 
 
 
 
1.5 Problem Statement 
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Over the years, the Botswana Ministry of Health has shown great commitment in the fight against 
TB through the adoption of many strategies including: the Directly Observed Therapy (DOT) 
which was adopted and implemented throughout the country; improved diagnosis of TB through 
training of laboratory staff (MoH Botswana, 2013), and the introduction of innovative technology 
(Gene Xpert) to rapidly diagnose TB (Agizew et al., 2012). Health care workers were trained on 
case detection and management of TB. Other strategies implemented include the provision of 
community based TB care, free TB care and treatment, and the linkage of the TB and HIV 
programmemes. 
Despite the interventions to curb the threat of TB driven by HIV infection, the prevalence of TB 
and the associated mortality remains very high (MoH Botswana, 2013). Tuberculosis is a curable 
disease that should not necessarily result in death. However, many deaths are recorded and appear 
to be increasing related to HIV (MoH Botswana, 2013). The provision of free HIV and TB 
treatment in all public hospitals and clinics has not reduced mortality among patients especially 
those co-infected with TB and HIV. Access to health services in Botswana (particularly in 
Francistown) is made easy by the availability of facilities within proximity to residential areas. 
Clinics are within an eight kilometre radius, simplifying access, especially in the towns and cities. 
Tuberculosis awareness has greatly improved through the collaborative efforts of different 
community based organisations that are actively working to support the TB programmeme through 
community mobilization, TB related health education and promotion, and contact tracing. Patients 
presenting for TB care and treatment at the clinics have diverse characteristics in terms of age, co- 
morbidities, socio-economic status, habits or lifestyle, educational status, TB classification 
(pulmonary or extra-pulmonary), TB severity (drug sensitive or drug resistant TB), smear 
microscopy results (smear negative or positive), TB grouping (new or retreatment), and TB 
treatment outcome (completed treatment, died or defaulted treatment). These different patient 
characteristics impact on death as a possible TB treatment outcome. 
Despite the significant investment in TB care and treatment,many adult patients treated for TB in 
Francistown clinics died before completing treatment. No study has been done in Botswana to 
characterize patients that died while on TB treatment. This study investigate TB reported deaths 
among adult patients treated between January 2010 and November 2015 to identify patient-related 
factors and early warning signs (predictors) of death among TB infected patients accessing care 
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1.6 Study setting 
 
The Botswanan health care delivery system is based on the primary health care model that is made 
up of public, private for-profit, private non-profit and traditional medical practices. The public 
sector makes up about 98% of the health facilities (AHO, 2016). These facilities include three 
referral hospitals, 15 general hospitals, 17 primary hospitals, two mission hospitals, three private 
hospitals, 289 clinics, 350 health posts, and more than 900 mobile stops. Thus, 85% of the 
population is located within eight kilometres of a health facility (AHO, 2016). Botswana has a 
well-established free national TB and HIV treatment programmeme for citizens, while non- 
citizens pay for health care services at public health facilities. In 2011 Botswana implemented 
nationwide six-months Isoniazid Preventive Therapy (IPT) among PLWH who have not started 
ART following the demonstration of the preventive advantage of IPT against TB in PLWH in 
clinical trials (Bucher et al., 1999, Woldehanna et al., 2004, Mwinga et al., 1998). 
Francistown is the second largest city in Botswana with a population of about 100,000 people. It 
is situated in the north-eastern part of Botswana about 90 kilometres from the Zimbabwean border. 
The Francistown population access medical services at facilities comprising one referral hospital, 
25 public clinics, 13 health posts and 22 private clinics. The public clinics are under the 
administration of the Francistown District Health Management Team (DHMT). The study will 
focus on the public health facilities within Francistown city, which are located within the different 
residential settlements around the city. The TB programmeme uses DOT and community TB 
strategies. Patients infected with TB receive treatment and care in the clinic within their residential 
area. The TB record for each patient is kept at the local clinic and an aggregated TB record from 
all the clinics is captured in the District electronic TB register (ETR) under the supervision of the 
District TB Focal person. 
1.7 Purpose 
 
The purpose of the study was to analyse patient-related factors and early warning signs (predictors) 
of death among patients infected with TB who are on treatment in Francistown. Findings from this 
study could help inform health care providers about patients on TB treatment who need close 
monitoring and special attention so as to prevent the possibility of this group of patients dying 
while on treatment. The findings could also be useful for the TB Programmeme Managers who 
review TB treatment protocols. Also, information from this study could potentially equip staff 
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caring for these patients at the local clinics to identify and closely monitor patients showing early 
warning signs indicative of high risk of dying while on treatment. 
1.8 Summary 
 
Tuberculosis continues to be a global emergency and accounts for millions of deaths annually. 
Botswana like other countries with a high prevalence of HIV, has witnessed an increase in the 
number of TB cases and increasing number of death associate with TB. Tuberculosis treatment is 
free, with patients accessing care from the Public Health facilities. This study will analyse patient- 
related factors and early warning signs (predictors) of death among patients infected with TB in 
Francistown using TB records from the Francistown district ERT. The next chapter will focus on 
reviewed literature relevant to the subject matter of this study. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Introduction 
 
Reported mortality among tuberculosis (TB) patient is still high in many countries around the 
world. In this chapter relevant information about TB mortality in the literature is discussed. 
Findings from other researchers working on mortality among patients infected with TB were 
reviewed in terms of the nature of the study population, study setting, and main findings. The 
review focused on the epidemiology of TB, causes of TB mortality and the risk or predictors of 
death among patients while on TB treatment. 
2.2 Epidemiology of Tuberculosis 
 
Tuberculosis remains one of the world’s deadliest communicable diseases (WHO, 2014) and is 
ranked among the top ten causes of death worldwide especially in Asia and Africa (WHO, 2008 
& 2009). The disease is reported to be responsible for 26% of avoidable adult deaths in developing 
countries (Bloom & Murray, 1992). In an effort to reduce the mortality associated with TB, the 
Millennium Development Goals (MDG) prioritised the reduction of death associated with TB by 
half by 2015 (WHO, 2010). In 2013, an estimated 1.5 million people died from the disease (WHO, 
2014). The global case fatality is reported to be between 7% and 35% (Chou et al., 2014). In the 
era of HIV/AIDS, the weakening of the immune system in HIV-positive individuals has greatly 
contributed to the increase in the case fatalities (Zachariah et al., 2002, MOH, 2007, Etard et al., 
2006). The majority of TB reported cases are in South Asia and the African regions, with sub- 
Saharan Africa carrying the largest burden of the disease (UN, 2010). Botswana has one of the 
world’s highest incidences of TB (NTP report, 1999, Kenyo et al., 1999). 
2.3 Causes of TB mortality 
 
The World Health Organisation (WHO) defines TB mortality as any TB cases dying during 
treatment regardless of the cause (WHO, 1994). Over the years, several studies have been done on 
the subject of TB mortality focusing on the cause of death among TB cases, the risk factors for 
death while on treatment, and predictors of death among HIV-positive and HIV-negative 
populations. Many of these studies have reported that other conditions apart from TB may be the 
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cause of death while a patient is on TB treatment (Cayla et al., 2004, Venkatarama et al., 1998, 
Bustamante-Monte et al., 2000, Harries et al., 2001, Gustafson et al., 2007). Korenromp et al. 
(2009) and Saraceni et al. (2008) reported that death due to TB may actually be under-documented 
or misclassified depending on the method used to estimate mortality. At present, deaths in 
treatment cohorts cover a small subset of all estimated TB deaths, as deaths are missed among 
patients who are never diagnosed, those who default or fail treatment, and among patients with 
untreated recurrent TB or TB sequelae (Korenromp et al., 2009). Some of the deaths in the TB 
treatment cohort are TB-related or caused primarily by TB infection, while other reported deaths 
are clearly not TB-related e.g. death from other co-morbidities (cancer, hypertension, diabetes, 
kidney and liver failure) or other disease complications, automobile accident or suicide. For this 
study, the cause of death in the TB treatment cohort will not be considered. The treatment outcome 
among TB patients on treatment will be grouped as either completed treatment and alive or died 
while on TB treatment. 
2.4 Risk factors or predictors of death among TB patients 
 
Several risk factors or predictors have been found to be associated with death among patients on 
TB treatment. The literature review in this section will discuss these risk factors or predictors of 
death under the following headings demographic factors (age, gender), socio-economic factors 
(homelessness, malnutrition, level of education and patient’s behaviour), and clinical conditions 
including - nature of TB (Pulmonary TB (PTB) or Extra-Pulmonary TB (EP-TB)), severity of TB 
disease (Multi-Drug Resistant TB (MDR-TB) and Extensively Drug Resistant TB (XDR-TB)), 
category of patient (new or retreatment), sputum smear result, and co-morbidity. Review of 
different works by other researchers working on death among TB patients will be discussed with 
a focus on their study setting, timing of the study, study design and main findings. This study will 
look at how these risk factors affect mortality among patients on TB treatment in Francistown 
clinics. 
2.5 Demographic factors 
 
2.5.1 Age 
 
Different TB mortality studies in South Africa (Pepper et al., 2015, Nigel et al., 2014), the United 
States (Pratt et al., 2011), Queensland, Australia (Walpola et al., 2003), Thailand (Anunnatsiri et 
al., 2005), Taipei-Taiwan (Yena et al., 2012, Wu et al., 2014), Israel (Shuldiner et al., 2014), 
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Shanghai, China (Xin et al., 2009) and Saudi Arabia (Abouzeid et al., 2013) all showed a positive 
correlation between TB mortality and age. In a study conducted in Mexico, Najera-Ortiz et al. 
(2008) reported that those aged 45 years and over have a higher risk of TB mortality. Ekaterina et 
al. (2012) also reported age above 45 years as an independent predictor of death in a large 
multicentre retrospective cohort study among MDR-TB patients on DOT programmeme in Russia, 
Latvia, Estonia, Peru and the Philippines. In a retrospective cohort study conducted over seven 
years in an aging population in a city in Taiwan, advancing age was associated with death while 
on TB treatment (Lin &Yen, 2015). The two South African studies, one among Platinum miners 
(Nigel et al., 2014) and a retrospective cohort study among TB patients in a community with high 
prevalence of HIV (Pepper et al., 2015), also reported age as a predictor of death. 
2.5.2 Gender 
 
Gender disparities in the epidemiology of TB disease and TB treatment outcomes have been 
reported by different researchers. The impact of gender on TB treatment outcome in the literature 
has revealed inconsistent results (Feng et al., 2012). Some studies reported that males are at a 
higher risk of dying while on TB treatment in India, Israel, Brazil, China, Singapore Taiwan 
(Santha et al., 2002, Shuldiner et al., 2014, Duarte et al., 2009, Xin et al., 2009, Low et al., 2009, 
Feng et al., 2012). In the prospective observational study in Taiwan, Feng et al. (2012) reported 
that a greater proportion of the study population that died were older males with more co- 
morbidities, who smoked more, and had a lower two-month sputum conversion rate compared to 
their female counterparts. 
Contrary to most studies, a retrospective cohort study conducted in South Africa reported females 
to be at a higher risk for death among TB patients (Pepper et al., 2015). A prospective cohort study 
of patients who began treatment for TB between June 1999 and May 2000 in Spain reported that 
gender was not associated with fatality (Cayla et al., 2004). 
2.6 Socio-economic status 
 
Socio-economic status (SES) has been shown to impact on health-seeking behaviour and thus 
impact on the treatment outcome of many chronic disease conditions (Kim et al., 2014, Elgart et 
al., 2014). The history of TB has shown a strong link between the disease and SES, with the disease 
historically being associated with poverty and people of a lower SES (Holtgrave & Crosby, 2004, 
Figueroa-Munoz  &  Ramon-Pardo,  2016,  Harling  et  al.,  2008,  Cramm  et  al.,  2011).  This 
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assumption still remains true in many impoverished communities. However, TB is not primarily 
the disease of the poor or people of low SES alone. In a cohort study in Norway to determine the 
regional and socio-economic differences in TB incidence and mortality, Liestol et al. (2009) 
reported that the difference in all-cause mortality is partly linked to socio-economic factors. Lin 
and Yen (2015) however reported a strong correlation between SES and TB mortality among the 
elderly TB patients in Taiwan. 
2.6.1 Malnutrition 
 
Malnutrition and TB are both problems of considerable magnitude in most of the underdeveloped 
regions of the world and closely linked with SES (Gupta et al., 2009). It has been found that 
malnourished patients with TB have delayed recovery and higher mortality rates than well- 
nourished patients (Gupta et al., 2009). Malnutrition has been proven to be a risk factor for TB 
mortality in different settings around the world (Gustafson et al., 2007; Santha et al., 2002; 
Zachariah et al., 2002; Malto et al., 2006; Zahar et al., 2001). In a prospective cohort study in 
Malawi, Zachariah et al. (2002) reported that moderate to severe malnutrition was a risk factor 
associated with early mortality. In another prospective study in Guinea-Bissau, Gustafson et al. 
(2007) reported an association between malnutrition and death among HIV-positive and HIV- 
negative patients. In a prospective cohort study among hospitalised patients in north-east Brazil, 
low serum albumen was associated with in-hospital death due to TB (Maltos & Moreira Lemos, 
2006). Maltos and Moreira Lemos (2006) report similar findings as Okamura et al. (2013) who 
conducted a prospective cohort study in Japan and reported hypoalbuminemia as a predictive risk 
factor for in-hospital mortality in patients with TB. 
2.6.2 Level of education 
 
Education has also been recognized as an economic status marker; in this case, lower education 
may be associated with lack of resources, overcrowding and unsanitary conditions (Chung- 
Delgado et al., 2015). The level of education of patients has an impact on adherence to treatment 
and better understanding of the disease condition and treatment (Hoa et al., 2004, Sanchez- 
Barriga, 2015). Level of education among TB patients is reported to have a positive correlation 
with mortality (Najera-Ortiz et al., 2008, Lin & Yen, 2015, Yena et al., 2012, Delgado et al., 
2015). Hoa et al. (2004) associated a lower level of education with poor understandings of TB, 
leading to poor outcomes including death. In a cohort study conducted in China among MDR-TB 
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cases, Sun et al. (2002) found that a lower level of education among the study population was 
associated with the risk of mortality. This is similar to the findings among MDR-TB population 
in Peru (Delgado et al., 2015). In a study in Mexico, individuals not completing elementary 
school showed to have a higher risk of dying from Pulmonary TB (Sanchez-Barriga, 2015). 
2.6.3 Patient’s behaviour 
 
Patient behaviour is influenced by their SES status. Patient behaviour is an important factor that 
could promote or adversely affect health as well as influence treatment outcome. Patient behaviour 
has been shown to influence TB test-seeking behaviour (Ford et al., 2009), compliance to 
treatment, default, treatment failure and death (Santha et al., 2000, Cayla et al., 2004, Pablos- 
Mendez et al., 1996, Barker et al., 2006, Waitt & Squire, 2011). Santha et al. (2002) reported 
delays in care seeking by patients in India as an important risk factor for death among male patients 
treated in a directly observed treatment strategy (DOTS). In a cross-sectional study among the 
Peruvian Amazon community, Ford et al. (2009) corroborated findings from Santha et al. (2002). 
In an observational study among HIV-infected patients co-infected with TB in New York City, 
Pablos-Mendez et al. (1996) reported that patients who started TB treatment after a 1-month delay 
died. In a cohort study in a rural South African setting with high burden of TB by Waitt and Squire 
(2006), treatment delay due to visiting a traditional healer had dire consequences for the patients. 
Literature also reports alcohol and substance misuse as risk factors for death among TB patients 
(Waitt & Squire, 2011, Cayla et al., 2004). Contrary to other study reports on the effect of alcohol 
consumption on treatment outcomes and mortality, an Iranian study among TB-HIV patients 
reported no significant association between smoking, drug and alcohol abuse (Tabarsi et al., 2012). 
2.6.4 Homelessness 
 
Homelessness is associated with people of low SES. In a study to determine risk factors for death 
among TB patients in a rural settlement in Russia where the WHO global TB control strategy was 
being implemented, Dewan et al. (2004) reported that high TB fatality was linked to homelessness 
among the study population. Findings of a prospective cohort study on status of treatment 
completion and fatality among TB patients in Spain also reported an association between 
homelessness and fatality (Cayla et al., 2004). In a retrospective study in the city of Sao Paulo in 
Brazil between 2002 and 2013 to determine the impact of homelessness on unsuccessful outcome 
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of treatment of pulmonary TB, Ranzani et al. (2016) reported homelessness as an important 
contributor to treatment failure including death. 
The SES factors discussed above impact on the health seeking behaviour of patients as well as the 
treatment outcomes including death. In this study, the effects of SES on TB mortality are not 
investigated due to the challenge of collecting these data retrospectively.These variable are either 
not recorded or poorly documented at the clinics. 
2.7 Clinical conditions 
 
Patients present with different types of TB disease which have varying impacts on the treatment 
outcome, including death. The presentations of TB disease, PTB or EPTB, MDR-TB or XDR-TB, 
and other co-morbidities are the different factors that could complicate diagnosis, delay or prolong 
treatment and impact on the possible treatment outcomes. These clinical presentations pose a 
serious challenge especially in resource limited settings. 
2.7.1 Nature and severity of TB infection 
 
The type and site of the TB infection have varying impacts on the treatment outcomes. Extra- 
pulmonary TB (EPTB) and drug-resistant TB (MDR-TB and XDR-TB) are associated with 
higher mortality rates than PTB. The WHO estimated 450,000 new cases of MDR-TB in 2012 
(WHO, 2013). Dalton et al. (2012) and Mitnick et al. (2008) reported that XDR-TB account for 
6% of drug-resistant TB cases. Multidrug resistant TB and XDR-TB forms of TB are difficult to 
treat and require many months of therapy (Bonilla et al., 2008) using multiple drugs with toxic 
effects (Chung-Delgado et al., 2011). Extra- pulmonary TB is difficult to diagnose in most 
resource-constrained settings and often results in patients being misdiagnosed and starting TB 
treatment when they are critically ill (Ya Diul et al., 2001). Thus, many TB patients with EPTB 
or drug resistant TB have a bad prognosis and an increased likelihood of dying. 
In a retrospective study among adult TB patients in an inner-city hospital in the United States 
between 1995 and 2001, Kourbatova (2006), reported EPTB as a persistent problem that is 
associated with high mortality. In another study Kourbatova et al. (2012) reported EPTB as an 
independent predictor of death among 1768 patients treated for TB in Estonia, Latvia, Philippines, 
Russia and Peru between 2000 and 2004. In another study in a high HIV prevalence population in 
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sub-Saharan Africa, a higher TB case fatality rate was associated with EPTB especially among 
smear-positive patients (Ya Diul et al., 2001). 
Reports from different studies have demonstrated a significant association between drug-resistant 
TB and mortality among TB patients on treatment in both HIV-positive and HIV-negative study 
populations. Pablos-Mendez (1996) reported MDR as a predictive factor for higher mortality 
among TB patients in an observational study in New York City. Santha et al. (2002) reported 
similar finding as Pablos-Mendez et al. (1996) in a population based study in Tiruvallur district of 
India involving 209 villages and nine urban clusters from 1999 to 2000. In a larger retrospective 
cohort study in Israel involving 4555 participants between 2000 to 2010, MDR was reported as a 
risk factor for death among the participants (Shuldiner et al., 2014). Other studies in Turkey 
(Babalik et al., 2013), Vietnam (Quy et al., 2006), Peru (Chung-Delgado et al., 2015, Kawai et al., 
2006), and Estonia (Lockman et al., 2001) showed a positive correlation between MDR-TB and 
increased fatality. Gandhi et al. (2006) reported a higher fatality rate among patients with XDR- 
TB in a South African study conducted in the KwaZulu-Natal province. Of the 1539 participants 
in the study, MDR-TB was diagnosed in 221 participants of whom 53 had XDR-TB. Fifty two of 
53 patients with XDR-TB died, with median survival of 16 days from time of diagnosis (Gandhi 
et al., 2006). 
2.7.2 Category of patients 
 
Patients with TB can be classified or grouped as new (no previous history of TB disease) or 
retreatment (previous history of TB disease). Some studies (Santha et al., 2002, Quy et al., 2006, 
Jonnalagada et al., 2011, Chung-Delgado et al., 2015, Field et al., 2014) have reported a higher 
mortality rate among retreatment patients compared to patients that have no previous history of 
TB infection/treatment. In a study carried out in South Africa by Field et al. (2014) where they 
studied the timing, rates and causes of death within the TB programmeme, they found the 
percentage of deaths among the retreatment patients to be twice that of the new patients. Their 
findings are in agreement with findings from Jonnalagada (2011) who reported a relative risk of 
mortality of 1.98 among patients with previous history of TB that are on TB treatment in Andhra 
Pradesh, South India. Santha et al. (2002) also found that previous history of TB was a risk factor 
for death in South India. Babalik et al. (2013) also noted that patients with a previous history of 
TB, and third month positive microscopy were at a higher risk of death in a case-control study in 
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Turkey between 2006 and 2009. Also, Chung-Delgado et al. (2015) found that there was a higher 
risk of death among MDR-TB with previous history of TB in a retrospective cohort study in Peru. 
Contrary to most reported findings, Albuquerque et al. (2014) conducted a prospective cohort 
study among PLWH on TB treatment in Brazil and reported that a previous history of TB does not 
predispose them to a higher risk of death while on TB treatment. 
2.7.3 Co-morbidity 
 
Studies have reported the impact of co-morbidity as a predictor of death among patients on TB 
treatment (Chou et al., 2014, Tarika & Tekabe, 2015, Agbor et al., 2014, Pacharee et al., 2012, 
Nigel et al., 2014, David et al., 2010, Xin et al., 2009, Shuldiner et al., 2014). The impact of HIV 
infection in worsening the TB disease and TB/HIV-related mortality has been well documented 
(Horne et al., 2010, WHO, 2008, Lawn & Wood, 2011, Chou et al., 2014). The effect that HIV 
infection has on patients with TB disease can be measured by the high TB notification rates and 
the reported case fatalities in settings with high prevalence of HIV (Pepper et al., 2015). Countries 
with high HIV infection rates report that HIV is one of the main reasons for failure to achieve TB 
control targets (WHO, 2004). In a meta-analysis, Straetemans et al. (2011) reported a threefold 
increase in the percentages of death among TB patients who were HIV-positive. 
Other co-morbidities that have been reported to be associated with death among TB patients on 
treatment include- hypertension (Erhobor et al., 2006), malignancy (Chou et al., 2014, Fernanda 
et al., 2005), influenza (Sibongile et al., 2015), liver cirrhosis (Erhobor et al., 2006), renal failure 
(Chou et al., 2014, Erhobor et al., 2006, Fielder et al., 2002), malnutrition (Erhobor et al., 2006, 
Gustafson et al., 2007, Okamura et al., 2013, Santha et al., 2002, Zachariah et al., 2002, Malto et 
al., 2006, Zahar et al., 2001), heart failure (Erhobor et al., 2006), and Diabetes mellitus (Subbanna 
et al., 2011, Baker et al., 2011, Faurholt, 2013, Fielder et al., 2002). 
2.8 TB Mortality in Botswana 
 
Literature on TB mortality in Botswana is scant, though the national TB and HIV programmeme 
continues to report a high incidence of TB cases especially among HIV-positive people. Due to 
the devastating effect of HIV/TB co-infection (Rana et al., 2000, Etard et al., 2006, MOH, 2007), 
the TB and HIV programmeme have been linked in all health facilities across the country. 
Oeltmann et al. (2008) conducted a TB treatment outcome study among children in Gaborone and 
Francistown and reported that younger children (less than five years old) with TB were twice as 
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likely to have death as an outcome of TB treatment compared to older children. In a post-mortem 
study conducted among 128 predominantly HIV-positive hospitalized patients in Francistown, TB 
was diagnosed in 40%; and it accounted for 36% of death in the study group (Ansari et al., 2002). 
Though the study sample was small, the study established the importance of TB as an opportunistic 
infection and cause of death among the HIV-positive population (Ansari et al., 2002). In another 
study conducted in 1997 by Steen et al. (2001) using data from all health facilities (excluding 
private sector), TB was reported to be the main cause of death among in-patients (16%). These 
studies conducted in Botswana highlight that TB is responsible for reported mortality among 
patients with TB and within the HIV-positive population. However, none of the studies looked 
into the predictors of death among TB patients. 
2.9 Review of research methodology 
 
Most of the studies on TB mortality were retrospective studies relying on past patient medical 
records from the clinics or hospitals (Agbor et al., 2014, Ansari et al., 2002, Erhobor et al., 2006), 
or records from the Regional or District TB records (Horne et al., 2010, Kaplan et al., 2014, Chung- 
Delgado et al., 2015, Lin et at., 2006). These retrospective studies reported limitations relating to 
the unavailability of relevant TB patient data for analysis and incomplete patient medical records. 
Some of the studies (Bustamante-Monte et al., 2000, Najera-Ortiz et al., 2008) were conducted in 
a single centre in a region thus their results cannot be generalized to other regions. Most of the 
studies did not consider people who defaulted treatment in their analysis hence the reported 
mortality rates may be higher than what was reported as some of the defaulters may have died 
(Najera-Ortiz et al., 2008). Some other researcher used the prospective cohort study design to find 
the association between different patients’ demographic and clinical conditions with mortality 
among patients with TB (Albuquerque et al., 2014, Matos et al., 2006, Cayla et al., 2004). 
2.10 Aim and objectives of this study 
 
The previous sections of this chapter provided a review of the different factors that contribute to 
mortality among patient on TB treatment in different settings. This study assessed patient-related 
factors and early warning signs (predictors) of death among patients with TB who were treated in 
Francistown clinics. 
The objectives of the study were to: 
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1. Determine the socio-demographic profile of adults (≥18 years of age) TB patients on 
treatment. 
2. Determine demographic and clinical factors associated with death while on TB treatment. 
 
3. Investigate early predictors of time to death among patients on TB treatment. 
 
2.11 Summary 
This chapter reviewed a selected array of relevant literatures on the factors that contribute to TB 
mortality and predictors of death among patients on TB treatment. Chapter Three will highlight 
the research methods used in this study. 
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Chapter 3 
Research Methodology 
3.1 Introduction 
 
This chapter highlights the research methods used in this study. This epidemiological study 
employed quantitative research methods to collect and analyse patient-related variables that are 
routinely recorded at the clinics during the treatment and care of TB patients. These data are 
recorded on the Facility TB Treatment Card as part of the routine standard treatment procedures 
of patients enrolled for TB treatment. The facility TB treatment records for all the clinics are 
captured in District Electronic Tuberculosis Register (ETR). This study attempted to identify risk 
factors or predictors of death among TB patients on treatment in all clinics in Francistown. The 
study consists of secondary data abstracted from the ETR from January 2010 to November 2015. 
No contact was made with the patients during the study period. Statistical analyses were 
conducted using STATA (version 13.1) software. 
3.2 Research design 
 
A retrospective case-control study design was used in this study. All TB records from January 
2010 to November 2015 were reviewed and data extracted for all eligible patients from the district 
ETR. This study design was chosen as it can yield important scientific findings with relatively 
little time, money, and effort compared with other study designs (Schulz & Grimes, 2002). The 
case-control study design allowed the determination of the association of different predictor 
variables to mortality within the study population. This study design was ideal in the Francistown 
context as the health facilities have a well-established TB programme with patients’ TB treatment 
records documented in a facility TB register. The information in the facility paper based TB 
registers from all the clinics is entered into the ETR at District level. In this study, the cases 
(patients who died while on TB treatment) were compared with the controls (patients with TB who 
completed treatment within the study time frame). Different researchers have used the case-control 
study design to measure the association of different variables with treatment outcomes in patients 
with TB in different settings (Duarte et al., 2009, Babalik et al., 2013, Oeltmann et al., 2008, Boccia 
et al., 2011). Parhar et al. (2015) used a case-control study design in determining if early TB death 
among cases in the province of Alberta in Canada was associated with increased TB transmission. 
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In the Parhar et al. (2015) study, cases and controls were matched using age, sex, population group, 
and positive/negative smear status 
3.3 Study population 
 
The study population was made up of all patients ranging from 18 years and above with 
documented confirmed TB diagnosis by routine Acid-Fast Bacillus (AFB) smear microscopy, 
culture, MTB/RIF Xpert result or chest x-ray that were registered for TB treatment in Francistown 
clinics, and were resident in Francistown during the treatment period. For the purposes of this 
study and access to treatment data, data from patients residing in the study area until death or 
completion of treatment were included. Absence of nationally linked electronic records across the 
country did not allow for inclusion of patients who were transferred out of the study area. 
Cases: All patients who had a treatment outcome of “died” while on treatment between January 
2010 and November 2015. 
Controls: All patients who had a treatment outcome of “completed treatment” while on treatment 
between January 2010 and November 2015. 
Inclusion criteria: 
 
• All forms of TB cases (pulmonary TB (PTB), Multidrug Resistant TB (MDR) and Extensively 
Drug Resistant TB (XDR) with or without any other co-morbidity were included in the study 
• Patients who had a treatment outcome of either “died” while on treatment or “completed” 
treatment 
• Patients residing in the study area for the duration of treatment or until death occurred. 
Exclusion criteria: 
• Patients with incomplete records (treatment outcome unknown) 
 
• Transfer out patients whose follow-up data is not accessible 
 
(NOTE: ETR databases across health districts are not linked in Botswana). 
 
3.4 Sampling strategy 
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No sampling was carried out. All eligible patients on TB treatment from January 2010 to 
November 2015 were included in the study. This time frame gave information on the 
characteristics of TB mortality in the Francistown health facilities during the study period 
3.5 Sample size consideration 
 
A census sampling approach was conducted. All eligible TB cases recorded in the ETR within the 
period of the study were included in the data analyses. 
3.6 Data sources 
 
The source of data for the study was the District ETR. Individual patient data from the facility- 
paper based TB register are entered into the ETR. The ETR is under the supervision of the District 
TB coordinator who oversees the activities of the TB programmeme in all the health facilities in 
the district. 
3.7 Data collection 
 
The study involved collection of TB patient related data using a data extraction form (Appendix 
4) by the researcher with the assistance of the District TB Coordinator. Data collection involved 
extraction of secondary data that are documented during TB treatment at the clinic. Data extracted 
from the ETR using the data extraction sheet were entered into an access database that is password 
protected. Data from the access database were later exported to an excel spreadsheet for analyses. 
Patient identifiers (Clinic Registration numbers) werestored in a lockable cabinet that the 
researcher alone has access to as a way of protecting the confidentiality of patients. No contact 
was made with participants nor were their medical records reviewed. Data used in this study were 
data collected under the Botswana National Tuberculosis programmeme. The different variables 
of interest collected are: 
• Year of registration 
 
• Health facility 
 
• Age 
 
• Gender 
 
• Occupation (Student, Health Care Worker, Miner/Ex-miner and other) 
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• Patient weight 
 
• Treatment classification (Pulmonary TB or Extra-pulmonary TB) 
 
• Treatment group -New or retreatment (failure, default, relapse and other) 
 
• Sputum smear results (at months: 0, 2, 3, 6 and 8) 
 
• HIV status 
 
• HIV-related intervention-Antiretroviral Therapy (ART), Isoniazid Preventive Therapy 
(IPT) and Cotrimoxazole prophylaxis (CPT) 
• Treatment outcome (dead or alive) 
 
3.8 Data analyses 
 
Data exported into an excel spreadsheet was imported in STATA (version 13.1) for analysis. 
Descriptive analyses were used to describe the frequency and percentage of demographic 
variables (age, gender and Occupation) and clinical variables (disease classification, treatment 
group, sputum smear result, HIV status, HIV treatment, IPT history, Cotrimoxazole history, TB 
treatment outcome, weight at initiation and continuation phase of TB treatment). Categorical data 
were presented as percentages while continuous data were presented by the means and standard 
deviations for normally distributed variables; skewed data were presented as medians, maximum 
and minimum values and interquartile ranges. Association between TB death and selected 
categorical variables was done using Chi-square or Fishers’ exact tests where appropriate. 
Wilcoxon sign rank test was used to compare medians for continuous variables using selected 
groups. Univariate and multivariate logistic regression techniques were used to assess the 
predictors of death. Variables with p<0.2 in the univariate were included in the multivariate 
model. Gender and treatment group were included a priori. The variables used included: 
demographic variable (age, gender) and patient clinical variables (disease classification, 
treatment group, HIV status, HIV-related intervention, ART, CPT and IPT). Univariate and 
multivariate Cox regression analyses and Kaplan Meier curves were conducted to identify 
predictors of time to death while on TB treatment. All variables from univariate analyses were 
included a priori into the time to death multivariate model. The 95% Confidence intervals and p- 
values for these variables were computed. A p-value < 0.05 was considered statistically 
significant in the study. 
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3.9 Validity and reliability 
 
In general, the quality and method of collection of secondary data used for research purposes are 
not under the control of the researcher (Sorensen et al., 1998). Completeness and accuracy of the 
secondary data is very important as it affects the reliability of the results. The reliability of the 
District ETR was verified by comparing randomly selected patient information in the ETR with 
the facility based TB register. The ETR was chosen as the source of data as it is the system used 
by the National TB programmeme to aggregate TB reports from the different facilities. Individual 
patient TB related variables that are recorded on the facility TB register are entered into the ETR. 
The ETR is used to analyse and generate quarterly and annual TB report for the district. 
Internal validity of the study was enhanced by selecting the cases and controls from the same 
study population (all enrolled TB patients in all the local clinics within the study period). 
Selection and chance bias was minimized by including all the patients who meet the inclusion 
criteria within the study period in the cases and controls. Prior to data analyses, data cleaning 
was carried out to check for any abnormal and inconsistent data. The effect of confounding was 
evaluated by using multivariate regression analysis to find out the impact of individual variables 
on TB mortality. 
3.10 Ethical considerations 
 
Ethics approval was sought and obtained from the Senate Research Committee at the University 
of the Western Cape (Appendix 1) and the Botswana Human Research Development Committee 
at the Ministry of Health (Appendix 2) before conducting the research. Permission to extract 
patient data from the Francistown district ETR was obtained from the District Health Management 
Team (Appendix 3). No contact was made with participants and the study posed minimal risk to 
the patient whose records were abstracted. The research collected data that are relevant to the 
objectives of the study, the information was not used in such a way that could violate the dignity 
of the patient whose record is abstracted. Participants’ personal identifiers were not used during 
the study proceedings and in the manuscript. Data collected for analyses was kept secured on a 
computer that is password protected and was only available to study investigators. 
3.11 Summary 
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This chapter outlined the method employed in this study. This epidemiological study employed 
quantitative research methods to collect and analyse patient-related variables that are routinely 
recorded at the clinics during the treatment and care of TB patients. The next chapter presents the 
findings of this study 
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CHAPTER 4 
RESULTS 
 
4.1 Introduction 
 
This chapter presents the results of the study. The characteristics of the study population, including 
socio-demographic and clinical variables are described in summary descriptive statistics using 
tables and figures. Also presented, are the univariate and multivariate analyses of the predictors of 
death and the time to death among the study population using the Kaplan Meier plot. 
4.2 Socio-demographic characteristics of study participants 
 
A total of 1718 participants were included in the study across 18 health facilities in Francistown, 
Botswana. Ten year age categories were used in this study. The median age of the participants was 
35 years (IQR: 29, 42). Males accounted for 56.3% of the study population. Table 4.1 shows the 
summary of the key socio-demographic and clinical characteristics of the study participants. 
Weight and occupation of the patients were inconsistently documented in the ETR,thus they was 
not included in the analysis nor reported. 
Table 4.1: Socio-demographic and clinical characteristics (number and percentage) of patients 
enrolled on TB treatment in Francistown clinics, 2010-2015. 
 
 
Characteristics 
No. of 
Participants 
 
Percentage 
Gender 
Female 750 43.7 
Male 968 56.3 
Age (years) median age = 35 years (Q1, Q3: 29, 42) 
18 – 24 65 3.8 
25 – 34 178 10.4 
35 – 44 663 38.6 
45 – 54 502 29.2 
55 – 64 235 13.7 
> 65 75 4.4 
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Table 4.1: (Continue) 
Characteristics 
No. of 
Participants 
Percentage 
Year of Treatment Initiation 
2010 379 22.1 
2011 342 19.9 
2012 353 20.6 
2013 291 16.9 
2014 227 13.2 
2015 126 7.3 
Occupation 
Student 980 57.0 
Ex-miner 4 0.2 
Unknown 734 42.7 
HIV Status 
Negative 424 24.7 
Positive 1270 73.9 
Unknown 24 1.4 
 
 
4.2.1 Age by Treatment year 
 
There was an observed increase in the age of TB patient on treatment during the study period and 
a significant difference in the median age across the 6 years study period (p = 0.0034, Figure 4.1) 
from median age of 36.0 in 2010 to median age of 39.2 in 2015. 
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Figure 4.1: Age distribution of TB patients in Francistown clinics, 2010-2015. 
 
4.2.2 Age distribution by Gender 
 
The study population was made up of mostly males especially in the older age groups (> 45 years). 
Females were marginally (53%) more than the males within the 18 to 34 years group. Within the 
35-44 year age group, an equal proportion of both males and females was represented. However, 
males represent 64.3% of the study population within the age group of 45 years and above. 
4.3 Clinical characteristics of study participants 
 
Throughout the years included in the study, majority of the study participants had Pulmonary TB. 
The proportion of Pulmonary to extra-pulmonary TB did not significantly change over time (p = 
0.494; Figure 4.2). 
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Figure  4.2:  Distribution  of  TB  patients  by treatment  classification  (anatomical  site  of  TB 
infection) in Francistown clinics, 2010-2015. 
4.3.1 Treatment classification (anatomic site of TB infection) 
 
Across the years of treatment included in the study (2010-2015), the median age of participants 
diagnosed with extra-pulmonary TB was always higher than those diagnosed with pulmonary TB. 
The highest median age for both EP-TB and PTB in the study population was recorded in 2014. 
 
 
There was a statistically significant association between gender and type of TB or site of TB 
infection among the study population (p = 0.002). A higher proportion of EPTB was recorded 
among females compared to males in the study population (Figure 4.4). 
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Figure 4.3: Treatment classification (anatomical site of TB infection) by gender in Francistown 
clinics, 2010-2015. 
 
 
4.3.2 Treatment group (new/retreatment-previous history of TB infection) 
There was a statistically significant association between treatment group and gender (p = 0.003), 
age (p = 0.001), and HIV status (p = 0.026) among the study population (Table 4.2). The ratio of 
men to women was 1.2:1 among the new treatment group while it was 2:1 among the retreatment 
groups. Association between age and new treatment group was significant with the highest 
association noticed within the 25-34year and 35-44year age group. Also, a high association 
between HIV status and new treatment group was noticed. 
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Table 4.2: Characteristics of the study participants by treatment group, Francistown clinics, 
2010-2015. 
 
 
 
lue* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
&P-value generated from Wilcoxon Rank Sum Test 
 
4.3.3 TB Smear result 
 
Table 4.3 shows the smear result for the study population. A significant proportion of the patients 
had no smear result at month two, three and at treatment completion. 
 
Variable 
Treatment Group n (%) 
P-va 
 
 New Retreatment  
Gender 
Female 682 (90.9) 68(9.1)  
Male 835 (86.3) 133 (13.7) 0.0 03 
 
Age (years) 
Median (Q1, Q3) 34 (28, 42) 38 (32, 46) <0.001& 
 
18 - 24 
 
54 (83.1) 
 
11 (16.9) 
 
25 - 34 165 (92.7) 13 (7.3)  
35 - 44 606 (91.4) 57 (8.6)  
45 - 54 430 (85.7) 72 (14.3)  
55 - 64 197 (83.8) 38 (16.2)  
> 65 65 (86.7) 10 (13.3) 0.0 01 
 
HIV Status 
Negative 389 (91.7) 35 (8.3)  
Positive 1106 (87.1) 164 (12.9)  
Unknown 22 (91.7) 2 (8.3) 0.0 26 
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Table 4.3: TB smear result of study participants on TB treatment in Francistown clinics, 2010- 
2015. 
 
 
New Retreatment 
 
n 
 
 
 
 
 
 
 
 
 
Table 4.4 shows the TB smear results and treatment outcome for the retreatment TB group (patients 
with a history of TB). 
 
 
Table 4.4: TB Smear results and treatment outcome for the retreatment group of TB patients in 
Francistown clinics, 2010-2015. 
Treatment Smear Results at 3 months of TB Treatment 
 
Outcome Negative Positive No result Total 
Alive 94 (52%) 7 (3.9%) 79 (43.9%) 180 
Died 2 (9.5%) 1 (4.8%) 18 (85.7%) 21 
Total 96 (47.8%) 8 (4.0%) 97 (48.3%) 201 
Table 4.5 shows the TB smear results and treatment outcome for the new TB treatment group 
(patients with no history of TB). 
 
 
Table 4.5: TB Smear results and treatment outcome for the new treatment group of TB patients 
in Francistown clinics, 2010-2015. 
Treatment Smear Results at 2 months of TB Treatment 
 
Outcome Negative Positive No result Total 
Alive 801 (58%) 42 (3%) 534 (39%) 1,377 
Died 19 (14%) 2 (1%) 119 (85%) 140 
Total 820 (54%) 44 (3%) 653 (43%) 1,517 
Month Negative Positive No result Negative Positive No result  
n  N (%) N (%) N (%)  N (%) N (%) N (%) 
Month 0 490 (32%) 712 (47%) 315 (21%) 1517 47 (23%) 114 (57%) 40 (20%) 201 
Month 2 820 (54%) 44 (3%) 653 (43%) 1517 - - - - 
Month 3 - - - - 22 (11%) 2 (1%) 177 (88%) 201 
Month 6 628 (41%) 0 559 (59%) 1517 - - - - 
Month 8 - - - - 19 (9%) 0 182 (91%) 201 
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4.3.4 HIV-related intervention to prevent TB 
 
A large proportion of the HIV-positive TB patients had a record of being on ART, taking CPT, 
had history of IPT or a combination of these interventions to reduce the risk of TB infection (Figure 
4.4). 
 
 
Figure 4.4: HIV-related intervention to prevent TB infection in HIV-positive patients on TB 
treatment in Francistown clinics, 2010-2015. 
4.4 Predictors of death during TB treatment 
 
A total of 161 of the 1718 participants (9.37%; 95% CI 8.0-10.8) died during the course of TB 
treatment with more patients in the 35 to54 year age group dying. 
A univariate analysis of the study data showed that HIV status, extra-pulmonary TB and treatment 
default were associated with death while on TB treatment among the study population (Table 4.6) 
Multivariate analyses showed that being older, HIV-positive, having unknown HIV, being a 
retreatment patient, and having extra-pulmonary TB were independent predictors of death while 
on TB treatment in the study population (Table 4.6). 
none: 2.3% 
ART: 6.4% 
not documented: 
27.9% CPT: 17.1% 
IPT: 0.3% 
ART/CPT/IPT (any 
combination): 46.1% 
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Table 4.6: Univariate and multivariate analyses of the characteristics of 1718 tuberculosis patients 
associated with death during TB treatment, Francistown clinics, 2010-2015. 
 
 
Treatment Outcome Univariate analysis Multivariate analysis 
Variables 
 
 
death P 
N 
(N, %) 
OR (95% CI) 
value 
OR (95% CI) P value 
Gender       
Female 750 76 (10.1) 1    
Male 968 85 (8.8) 0.85 (0.62 - 1.18) 0.341 1.17 (0.84 - 1.64) 0.361 
 
Age (years) 
      
18 – 34 243 18 (7.41) 1    
35 – 54 1165 95 (8.15) 1.10 (0.66 - 1.87) 0.697 0.83 (0.48 – 1.47) 0.541 
≥55 310 48 (8.6) 2.29 (1.29 – 4.05) 0.004 1.82 (0.99 – 3.36) 0.054 
HIV Status 
 
Negative 
 
 
424 
 
 
19 (4.5) 
 
 
1 
   
Positive 1270 138 (10.9) 2.60 (1.59 – 4.25) <0.001 2.42 (1.44 – 4.07) 0.001 
Unknown 24 4 (16.7) 4.26 (1.32 – 13.70) 0.015 4.10 (1.23 –13.69) 0.022 
Treatment Group       
New 1517 140 (9.2) 1    
 
Retreatment 201 21 (10.5) 1.15 (0.71 – 1.86) 0.578 
 
Treatment classification 
6.84 (2.05 – 
22.76) 
 
0.002 
 
Pulmonary 384 51 (13.3) 1  
Extra- 
1334 110 (8.3) 1.70 (1.20 – 2.43) 0.003 1.62 (1.13 –13.69) 0.009 
pulmonary 
Retreatment classification 
     
New 1517 143 (9.4) 1    
Fail 27 2 (7.4) 0.37 (0.05 – 2.80) 0.342 0.07 (0.01 – 0.70) 0.024 
Relapse 162 14 (8.6) 1.00 (0.57 – 1.76) 0.990 0.14 (0.04 – 0.52) 0.003 
Defaulter 12 2 (16.7) 7.03 (2.2 – 22.4) 0.001 - - 
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4.5 Predictors of time to death while on TB treatment 
Time to death which is defined as the time from initiation of TB treatment to time of death while 
on treatment was analysed for all the 161 patients that died. The Cumulative mortality is shown in 
Figure 4.6. The overall median time to death in the study population was 52 days (Q1, Q2: 15 – 
112) with approximately 50% of the cases dying within 2 months of starting TB treatment. 
 
 
 
 
 
 
 
Figure 4.5: Kaplan Meier plot showing the cumulative mortality during TB treatment in 
Francistown clinic, 2010-2015. 
A univariate cox regression showed that there were no statistically significant differences in time 
to death by gender (HR = 0.92; 95% CI 0.67 – 1.26) and treatment classification (HR = 1.02; 95% 
CI 0.73 – 1.43). Participants with no history of TB showed to be more likely to die within 5 months 
of being on treatment (HR 1.36 95% CI 0.66 - 2.17. p= 0.187) though this observation was not 
statistically significant. After adjusting for gender; age at start of TB treatment, treatment class 
(pulmonary vs extra-pulmonary), treatment group (new vs retreatment), and HIV status, lack of 
HIV-related intervention during TB treatment was a significant independent predictor of time to 
death (adjusted HR = 1.79; 95% CI 1.03 – 3.1; p = 0.037). All participants without any form of 
HIV-related interventions died within 60 days of starting TB treatment (Figure 4.7) 
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Figure 4.6: Kaplan Meier plot showing the cumulative mortality by HIV treatment intervention 
during TB treatment in Francistown clinics 2010-2015. 
4.6 Summary 
Among the 1718 adult patients on TB treatment in Francistown health facilities from January 
2010 to November 2016 that were included in this study, a total of 161 (9.37%) died while on 
treatment. Analysis of the study data showed that 56% of the TB patients were male. Analysis of 
the result showed a significant difference in the median age across the study period (P=0.0034) 
from a median age of 36 years in 2010 to a median age of 39 years in 2015. Students make up 
57% of the study population. 
Predictors of mortality while on treatment include-being 55 years or older, previous history of 
TB, HIV-positive status, unknown HIV status and HIV-related interventions. In this study, 
gender was not a predictor of death. Antiretroviral therapy and CPT were found to be protective 
of death in the study. More than half of deaths recorded in this study occurred during the 
intensive phase of TB treatment. 
After adjusting for gender, age, treatment classification, treatment group and HIV status, lack of 
HIV-related interventions (ART and CPT) during TB treatment was a significant independent 
predictor of time to death among patients with TB/HIV co-infection in this study. Chapter five 
will discuss the implication of these findings. 
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CHAPTER 5 
DISCUSSION 
5.1 Introduction 
 
This chapter presents the discussion of the important findings of this study. The discussion focuses 
on the predictors of death and the predictors of the time to death among the TB patients who died 
while on TB treatment. The chapter will also discuss the interventions that were protective to death 
among the TB patients in the study. Other important findings of the study relating to smear result, 
gender, and treatment group and treatment classification will also be discussed. 
5.2 Predictors of death among patients on TB treatment in Francistown 
 
The mortality rate among TB patient in Francistown during 2010 to 2015 was 9.37%. Many 
factors have been associated with mortality among people on TB treatment in different settings. 
In this study the predictors of death among the patients on TB treatment in Francistown clinics 
include advancing age, HIV status, EPTB, a history of TB, treatment relapse and default, and 
HIV-related interventions. These important predictors of death are discussed below. 
5.2.1 Prior TB infection 
 
Univariate analysis showed that treatment group did not impact on death while on treatment. 
However, multivariate analysis showed a significant association between treatment group and 
mortality making retreatment group an important predictor of death. The mortality risk among the 
study population with previous history of TB after multivariate analysis was seven-fold higher 
among participants with a history of defaulting TB treatment. In this study, participants with a 
history of TB treatment failure and TB relapse showed to be at a higher risk of death. This finding 
corroborates reports from other studies (Santha et al., 2002, Najera-Ortiz et al., 2008, Kawai et al., 
2006,Field et al., 2014, Babalik et al., 2013, Jonnalagada et al., 2011 and Quy et al., 2006). It was 
observed in this study that many of the patients that completed TB treatment could not be classified 
as cured of TB as most did not have smear results at the completion of treatment. The potential 
implication of this, is that patients that are not cured after treatment will later develop TB again 
especially if they have a condition that weakens the immune system. Patients with poor adherence 
to TB treatment have a higher probability of developing MDR-TB (Sonnenberg et al., 2001, Zignol 
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et al., 2007), an aggressive form of TB which predisposes the patients to increased risk of death 
(Tocwue et al., 2005) while on treatment. Among the retreatment group, TB defaulters had the 
highest risk of mortality while on treatment. Some of the factors reported to be responsible for 
defaulting TB treatment in the literature include-patients’ economic situation (Johansson et al., 
1996), socio-economic status (Belo et al., 2011) and poor adherence (Zellweger et al., 1998). In a 
Botswanan study reported by Talbor et al. (1993), not knowing that death could occur from TB 
and not receiving counselling before the start of TB treatment were risk factors for defaulting 
treatment. 
5.2.2 Extra Pulmonary Tuberculosis 
 
Extra-Pulmonary Tuberculosis was a predictor of death while on TB treatment in this study. This 
finding is in agreement with findings of TB studies in Nepal (Sreeramareddy et al., 2008) and 
Ethiopia (Silesh et al., 2013). Extra-Pulmonary Tuberculosis is difficult to diagnose in many 
resource limited setting including Botswana which usually results in patients starting TB treatment 
in advanced state of the infection. Other co-morbidities also complicate the diagnosis of EPTB 
further delaying the start of treatment. 
5.2.3 HIV co-infection 
 
Univariate and multivariate analyses both show that being HIV-positive or having an unknown 
HIV status are predictors of death among TB patients in this study. Co-morbidities have been 
linked to increased mortality among TB patients on treatment in many previous studies (Chou et 
al., 2014, Tarika & Tekabe, 2015, Agbor et al., 2014, Pacharee et al., 2012, Nigel et al., 2014, 
David et al., 2010, Xin et al., 2009, Shuldiner et al., 2014). Among TB patients, HIV co-infection 
has been reported to increase the risk of mortality (Cayla et al., 2004, Horne et al., 2010, WHO, 
2008, Lawn & Wood, 2011, Chou et al., 2014). In this current study, there was a positive 
association between the 85.7% of patients who died with HIV-positive status; a finding that 
supports findings of the Botswana Ministry of Health (MOH, 2007) and other Botswana TB 
researchers’ results (Ansari et al., 2002, Steen et al., 2001). This finding gives credence to the 
need to screen for HIV in patients diagnosed with TB and have their HIV status documented in 
the TB records. 
5.2.4 HIV-related intervention 
 
 
 
 
38  
Result from this study showed that CPT and ART were effective in reducing mortality among TB 
patients. This finding further supports the assertion of many other reports regarding the protective 
ability of CPT and ART among TB patients co-infected with HIV (Zachariah et al., 2003, 
Mwaungulu et al., 2004, Woldehanna et al., 2004, Straetemans et al., 2011, Van’t Hoog et al., 
2012). Though the HIV treatment guidelines outline the importance of CPT in reducing TB 
infection and mortality among PLWH and HIV patients with immunological and virological 
failures, analysis of the study data showed that a significant proportion of the patients did not have 
documented use of CPT in their TB record. 
5.2.5 Age 
 
Age was not a predictor of death in the unadjusted and univariate analyses, but age became a 
predictor of death in the multivariate analysis. Among the study population, being older than 55 
years was predictive of death. Advancing age as a predictor of death has been reported in many 
studies (Sun et al., 2015, Pepper et al., 2015, Lin et al., 2015, Pratt et al., 2011). Some of the 
factors contributing to higher mortality among the older TB patients on treatment in other studies 
includes- reduced access to health services (Xin et al., 2009), malnutrition (Zachariah et al., 
2002, Gustafson et al., 2007, Matos et al., 2006), poor socio-economic status (Dewan et al., 
2004, Liestol et al., 2009, Cayla et al., 2004) and HIV and other co-morbidities (Anunnatsiri et 
al., 2005, Ruiz-Navarro et al., 2005, Shuldiner et al., 2014). Access to health services is not 
thought to influence mortality among the patients in this study as health care is free and health 
facilities are accessible within an eight kilometre radius of the population 
5.2.6 Gender 
 
Gender is an important factor in the epidemiology of many diseases including TB infection, 
progression to TB disease and mortality. In this study, gender was not a predictor of death or 
time to death. This finding is in agreement with findings from a study by Cayla et al. (2004), but 
contrary to many other studies. Many research findings have associated being male with a higher 
risk of death and time to death while on treatment (Santha et al., 2002, Schuldiner et al., 2014, 
Duarte et al., 2009). 
5.3 Predictors of time to death among patients on TB treatment in Francistown. 
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In this study, the risk of mortality was higher among patients in the first two months of TB 
treatment with approximately half of death occurring in the intensive phase of TB treatment. The 
overall median time to death was 52 days. This finding is similar to reported timing of mortality 
during TB treatment in a range of other studies (Birlie et al., 2015, Mathew et al., 2006, Walpola 
et al., 2003, Pepper et al., 2015, Harries et al., 2009, Ismail & Bulgiba, 2013). After adjusting for 
gender, age, treatment classification, treatment group, and HIV status, ART and CPT 
administration during treatment among TB patients co-infected with HIV were independent 
predictors of time to death in this study. All HIV-positive patients who were not on ART and or 
CPT died before completion of the two-month intensive phase of TB treatment. The short 
survival probability among TB/HIV co-infected patients in the study could be attributed to late 
presentation for treatment or institutional delays in initiating treatment, a weakened immune 
system, possible immune reconstitution inflammatory syndrome (IRIS), poor tolerability of the 
anti-tuberculosis drug or other co-morbidities. Further research is needed to solidify these 
speculations. Findings from this study clearly demonstrate the value of initiating ART on all 
HIV-positive patients infected with TB as soon as possible. The study also demonstrates the 
protective property of CPT among PLWH. 
5.4 Other interesting observations. 
 
Some interesting findings were made during the analyses of the study data. These findings could 
be potentially useful in patient care and management thereby contributing to better treatment 
outcomes among TB patients. These findings are presented below- 
5.4.1 Extra-pulmonary Tuberculosis among the study population 
 
A significantly higher proportion of EPTB occurred among female TB cases compared to males 
in the study population. This finding seems to be a new finding with no known study in Botswana 
reporting any association between female gender and EPTB. Different studies in India (Peto et al., 
2009), United States (Holmes et al., 1998) and Denmark (Zhang et al., 2011) all reported an 
association between EPTB and being female. Some of the factors thought to be associated with 
the high prevalence of EPTB among female include endocrine factors (Forssbohm et al., 2008) 
and smoking (Sreeramareddy et al., 2008 and Chiang et al., 2007). In this study, variables relating 
to smoking or tobacco use were not routinely documented in the TB treatment records, thus 
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association of smoking to a higher prevalence of EPTB in the female participants in the study 
could not be established. 
5.4.2 Smear result 
 
More than half of the study participants were diagnosed or started TB treatment without a 
documented smear result. The proportion of missing smear results in the study is much higher than 
those reported in other studies (Pepper et al., 2015, Shuldiner et al., 2014, Dewan et al., 2004, Xin 
et al., 2009). Studies in different settings have reported diverging results about the association of 
sputum smear positivity or negativity at the start of TB treatment to the risk of dying while on TB 
treatment (Harries et al., 1998, Ekaterina et al., 2012, Pepper et al., 2015, Xin et al., 2009). Though 
an alarming 85% of the patients that died while on TB treatment had no smear result either at the 
start of TB treatment or at the completion of the intensive phase of TB treatment; no inference 
could be drawn between smear result and death in the study population. 
5.4.3 HIV co-infection and HIV-related interventions among study population 
 
A high proportion of the study population (73.9%) were co-infected with HIV while on TB 
treatment between 2010 and 2015. This finding is in line with the findings of other researchers 
that reported a close association between TB and HIV infection (Shuldiner et al., 2014, 
Straetemans et al., 2011). TB/HIV co-infection have been documented to affect TB treatment 
outcome and mortality (Babalik et al., 2013, Albuquerque et al., 2014). This finding lends 
support to the assertion that all TB patients need to be tested for HIV and have a documented 
HIV status while on TB treatment. A large proportion of HIV-positive patients that were treated 
for TB in the study period had documented records of HIV-related interventions of either 
receiving one or a combination of antiretroviral therapy (ART), Isoniazid preventive therapy 
(IPT) or Cotrimoxazole prophylaxis (CPT). These interventions have been proven to reduce the 
risk of TB infection and mortality among HIV-positive individuals (Pepper et al., 2015, 
Manosuthi et al., 2008, Zachariah et al., 2001, Zachariah et al., 2003). In a bid to reduce the 
incidence of TB infection among PLWH, the BNTP recommends IPT for all HIV-positive 
individuals without active TB infection for a period of six months. The Botswana National ART 
Programme also recommends CPT for HIV-positive patients with CD4 counts of less than 200 
cells/µl; patients on ART with a detectable viral load; patients on ART with immunological and 
or virological failure and HIV-positive patients co-infected with TB. Though these 
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recommendations are in place, a sizeable proportion (27.9%) of the study population did not 
have a documented record of having received ART, CPT or history of receiving IPT. 
5.5 Limitations of the study 
 
As with all retrospective studies, this study had some limitations. Study findings may be subject 
to bias, random error and confounding. The occurrence of bias was minimised by using a 
standardised data abstraction form. Random error was minimised by including all 1718 TB cases 
that met the inclusion criteria in the study. The effect of confounding was minimised by using 
multivariate regression analysis including variables such as age, gender, HIV status, and 
treatment group and treatment classification. Other factors that may affect mortality such as co- 
morbidity, CD4 count if HIV-positive,weight, occupation and smear results were not included in 
the regression analysis due to non-availability (not documented) or inconsistencies of the 
variables. The routine data that were recorded in the ETR did not give information on the level of 
education, type of housing and economic status to allow for analysis of the effect of these 
variables on mortality. Some of the patients on treatment during the study period did not have a 
documented HIV status while on treatment. The exclusion of defaulters is another limitation in 
this study as some of the defaulters might have died and their death not reported to the facility to 
update the ETR. Thus, the reported mortality among the TB patients in the study period may be 
higher that was is reported. 
5.6 Summary 
 
This chapter presented the discussion of the important findings of this study in relation to the 
study objectives. The predictors of death identified in the study include: prior history of TB 
infection, EPTB, HIV status, HIV-related intervention and advancing age. Gender was not a 
predictor of death in this study. The independent predictors of time to death among the study 
population were HIV-related interventions (ART and CPT). Patients had the highest risk of 
dying in the first two months of TB treatment. Some other interesting findings in this study 
include the association of EPTB with female gender, the high proportion of missing smear 
results, and no documentation of HIV status and HIV related interventions among the patient on 
TB treatment. Finally, some of the limitations of this study were discussed. The next Chapter 
will present the recommendations and the conclusion of the study. 
 
 
 
 
42  
CHAPTER 6 
 
RECOMMENDATIONS AND CONCLUSION 
 
6.1 Introduction 
 
The previous chapter focused on the discussion of the important findings of the study. Notable 
findings of this study are the positive association between advancing ages, EPTB, HIV status, 
HIV-related intervention among TB-HIV co-infected patients, and a prior history of TB with 
mortality while on TB treatment. Most of the deaths in the study occurred during the intensive 
phase of TB treatment with all HIV co-infected cases dying during the first two months of 
treatment. Another notable finding is the high proportion of patients without a smear result at the 
beginning of TB treatment, during treatment and at the completion of treatment. This chapter 
presents the recommendations and conclusions of this study. The proposed recommendations 
will address the key findings reported in chapters four and five. 
6.2 Recommendations 
 
Based on the interesting findings and observations made while conducting this study and 
literature reviews, the following recommendations are proposed- 
Completeness of ETR 
 
Many important socio-demographic and clinical patient variables such as type of 
accommodation, type of occupation, level of education, smoking and tobacco use, patient’s 
weight, HIV status, HIV-related intervention, CD4 count, co-morbidity are not routinely 
collected in a lot of TB records. These variables are important in making decisions during TB 
care and management. These socio-demographic and clinical variables are important for 
monitoring and evaluating the TB programme as well as for research purposes. The 
incompleteness of the ETR makes it difficult to fully characterise study participants and analyse 
the impact of these variable on TB mortality. It is therefore recommended that data quality 
management measures be put in place to ensure that the ETR is complete and kept updated. 
TB Smear result 
 
A large proportion of the patients on treatment did not have smear results at the start of TB 
treatment, during treatment and at the completion of treatment. The non-availability of smear 
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results at the start of TB treatment implies that smear microscopy was not always used in TB 
diagnoses at the clinics in Francistown. Smear results are critical for TB diagnosis, monitoring 
the progress and success of TB treatment, and management of TB patients. The District Health 
Management Team (DHMT) needs to address the challenge with TB smear microscopy at the 
clinics. 
HIV status, HIV-related interventions and level of compliance to treatment guidelines 
 
Due to the high prevalence of HIV in this study and the study finding of the protective effect of 
ART, CPT and IPT among TB/HIV co-infected patients, it is recommended that all patients on 
TB treatment should have their HIV status documented; all HIV-positive patients should be 
initiated on ART as soon as possible and also be started on CPT. Strengthening of the TB/HIV 
services integration in the clinics is highly recommended. Compliance to treatment guidelines in 
terms of TB diagnosis and TB case management is crucial to the success of the Botswanan 
National Tuberculosis Programme. Studies are required to find out the level of compliance to TB 
treatment guidelines and shed light on the pattern of TB diagnoses at the clinics. 
Documentation of co-morbidity among TB patients 
 
Currently, only HIV as a co-morbidity is routinely documented in the patient’s TB record. The 
documentation of any other co-morbidities apart from HIV should be made routinely as different 
co-morbidities have been shown to predict mortality while on TB treatment. 
Need to establish cure status of patient after completion of TB treatment. 
 
The treatment completion rate does not necessarily equal to treatment cure rate. The cure rate is 
an important index in evaluating the effectiveness of the TB programme. If TB patients are 
treated properly and are cured, TB patients with previous history of TB in the system will be 
reduced with the potential to reduce the associated TB mortality rate. In light of the findings 
from this study, interventions to reduce defaulting TB treatment should be put in place at the 
clinics. All patients with a previous history of treatment default should be monitored closely to 
prevent defaulting on retreatment and the development of drug resistance. 
6.3 Conclusion 
 
Among the 1718 adult patients treated for TB in Francistown health facilities from January 2010 
to November 2016 that were included in this study, a total of 161 (9.37%) died while on 
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treatment. The predictors of death identified in the study include: prior history of TB infection, 
EPTB, HIV status, HIV-related intervention and advancing age. Gender was not a predictor of 
death in this study. The overall median time to death in the study was 52 days. Patients with no 
history of TB were likely to die within five months of being on TB treatment. All TB patients 
with HIV co-infection who did not receive ART and or CPT died during the intensive phase of 
TB treatment (first two months). More than half of the deaths recorded in this study occurred 
during the intensive phase of TB treatment. After adjusting for gender, age, treatment 
classification, treatment group, and HIV status - lack of HIV-related interventions (ART and 
CPT) during TB treatment was a significant independent predictor of time to death among 
patients with TB/HIV co-infection in this study. Thus, antiretroviral therapy and CPT were found 
to be protective of death in the study among TB/HIV co-infected persons. 
Some other interesting findings in this study include the association of EPTB with female 
gender, the high proportion of missing smear results and non-documentation of HIV status, and 
HIV related interventions among patients on TB treatment. 
The association between HIV and risk of mortality among TB/HIV co-infected patients was 
clearly demonstrated in this study. This finding implies that patients diagnosed with TB in these 
health facilities must have their HIV status established and appropriate HIV-related therapy 
administered to minimise the risk of dying while on treatment. Thus it is imperative in the light 
of this finding and many other reports to continue to strengthen the linkage between HIV and TB 
care and services. All patients seen at the HIV clinics should be screened for any underlying TB 
at every clinic consultation. 
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Appendix 3: Permission to use District ETR record 
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Appendix 4: Data abstraction form 
  DATA ABSTRACTION FORM   
1. Patient  study number: 
 
2. Age: (years)   3. Sex: Male Female 
 
3. Clinic:   
 
4. Occupation: 
Student Health care worker Miner/Ex Other 
 
5. Patient weight: 
Initiation phase: Month 1:  . kg Month 2:  . kg 
Continuation phase: Month 3:  . kg Month 4:  . kg 
Month 5:  . kg Month 6:  . kg 
6. Treatment classification 
Pulmonary Extra-pulmonary 
 
7. Treatment group 
New 
Retreatment: 
Failure Default Relapse Other 
 
8. Sputum examination for AFB: Result (*P/N) 
Month 0: Month 2: Month 3: Month 6: Month 8: 
 
9. HIV Status and interventions 
HIV:  Positive Negative 
*ART: Yes No 
*IPT: Yes No 
*CPT: Yes No 
10. Treatment Outcome:  Died Alive 
 
 
Key: 
 
*P: Positive test result. *N: Negative test result.*ART: Antiretroviral therapy.*IPT: Isoniazid Preventive 
Therapy. *CPT: Cotrimoxazole preventive therapy.*AFB: Acid Fast Bacilli. 
Failure: a patient who is started on a retreatment regimen after having failed previous treatment. 
Default: a patient who return to treatment, positive bacteriologically, following interruption of treatment 
for 2 months or more with smear or culture positive TB. 
Relapse: a patient previously treated for TB who has been declared cured or treatment completed, and is 
diagnosed with sputum smear positive or culture positive TB. 
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